-Genomewide association studies reported SLC22A2 variants to be associated with serum creatinine. As SLC22A2 encodes the organic cation transporter 2 (OCT2), the association might be due to an effect on tubular creatinine handling. To test this hypothesis we studied the association of SLC22A2 polymorphisms with phenotypes of net tubular creatinine secretion: fractional creatinine excretion (FE creat) and bias of estimated glomerular filtration rate (eGFR). We also studied the association with end-stage renal disease (ESRD) and graft failure (GF) in renal transplant recipients. SLC22A2 single nucleotide polymorphisms (SNPs), rs3127573 and rs316009, were genotyped in 1,142 ESRD patients receiving renal transplantation and 1,186 kidney donors as controls. GFR was measured with 125 I-iothalamate clearance. Creatinine clearance was also assessed. FEcreat was calculated from the simultaneous clearances of creatinine and 125 I-iothalamate. Donor rs316009 was associated with FEcreat (beta Ϫ0.053, P ϭ 0.024) and with estimated [modification of diet in renal disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)] but not measured GFR. In line with this, donor rs316009 was associated with bias of the MDRD and CKD-EPI but not the Cockroft-Gault equation. Both SNPs were associated with ESRD: odds ratios [95% CI] 1.39 [1.16 -1.67], P ϭ 0.00065, and 1.23 [1.02-1.48], P ϭ 0.042, for rs3127573 and rs316009, respectively. Neither SNP was associated with GF. Thus, SLC22A2 is associated with phenotypes of net tubular creatinine secretion and ESRD. creatinine tubular secretion; SNP; genetic polymorphism; GWAS; OCT2 GENOME-WIDE ASSOCIATION STUDIES (GWAS) identified a number of loci influencing renal function (7, 23, 24) usually using renal function estimates based on serum creatinine as a proxy for glomerular filtration rate (GFR).
function estimates based on serum creatinine as a proxy for glomerular filtration rate (GFR).
Serum creatinine, however, is determined not only by GFR, but also by the rate of creatinine generation, extrarenal elimination, and by tubular handling (5, 31, 35, 46, 49) . Dissecting the biological mechanisms underlying genetic associations with serum creatinine, therefore, is pivotal for proper interpretation of GWAS findings. In particular, it is relevant to assess whether loci associated with serum creatinine reflect susceptibility to renal damage (1) or, alternatively, reflect biological variations in creatinine generation or in creatinine handling unrelated to the risk for renal damage.
The SLC22A2 gene is associated with serum creatinine and estimated GFR (eGFR) (7). However, SLC22A2 might well be a creatinine secretion locus. First, SLC22A2 single nucleotide polymorphisms (SNPs) were associated with GFR estimated from serum creatinine but not cystatin C (23, 34) . Second, the SLC22A2 gene encodes the organic cation transporter 2 (OCT2), a predominant transporter involved in tubular creatinine secretion. It is expressed in the basolateral membrane of proximal tubule cells (29) , where it mediates creatinine uptake from the peritubular capillaries, as an initial step in tubular creatinine secretion (9, 29, 38, 51, 52, 59) .
Tubular secretion accounts for 10 -20% of urinary creatinine excretion (5, 35, 46) . Presence of tubular secretion as an additional mechanism of creatinine clearance translates into an acknowledged systematic error (bias) for creatinine-based GFR estimation methods (35, 45, 46, 49) .
In the present study we test the hypothesis that the association between genetic variation in the SLC22A2 locus and eGFR is due to association of SLC22A2 with tubular secretion of creatinine. To this purpose, we investigated first the association of SLC22A2 variants with fractional excretion of creatinine (FE creat ) as an intermediate phenotype for tubular creatinine secretion. Second, we tested the association of SLC22A2 with the bias of eGFR assessed by the modification of diet in renal disease (MDRD) and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. As a "negative control" we also tested the association of SLC22A2 with the bias of the creatinine clearance estimated by the CockroftGault equation, hypothesizing that SLC22A2 would be associated with bias of the MDRD and CKD-EPI equation, but not with that of the Cockroft-Gault equation as the latter is calibrated on creatinine clearance. Finally, we tested the association of SLC22A2 with end-stage renal damage in native and transplanted kidneys.
The studies were performed in the REGaTTA (REnal GeneTics TrAnsplantation, Groningen, the Netherlands) cohort (12, 40), a large single-center renal transplant cohort, in which we genotyped both donors and recipients. Since the SLC22A2 gene expression is restricted to the kidney with scarce extrarenal sites of expression (placenta, brain) [National Center for Biotechnology Information UniGene database (58)], donor SLC22A2 genotype largely represents kidney genotype; accordingly, we tested associations between the recipient phenotypes and the donor SLC22A2 polymorphisms. For this study we selected the two most prominent among previously characterized SLC22A2 polymorphisms: rs3127573 and rs316019. The first SNP, rs3127573 in the SLC22A2 5= region, was the top SNP reported for association with serum creatinine and eGFR creat (7). The other, a missense rs316019, is the most frequent coding variant in the SLC22A2 gene and is also the best functionally characterized. This polymorphism in the exon 4 results in an Ala270Ser amino acid substitution with functional consequences for the protein and was associated with impaired transport of OCT2 substrates in vitro (8, 15, 48, 57, 61) . Because genotyping of rs316019 was technically not possible in this study, we searched for another SNP to use as a proxy. Thus, rs316009, a highly correlated tag SNP in perfect linkage disequilibrium (LD: r 2 ϭ 1) in the SLC22A2 intron, was genotyped instead, assuming that it represents rs316019. Therefore, in the subsequent manuscript sections we refer to rs3127573 and rs316009.
METHODS
Study population. This study was conducted in the REGaTTA cohort, with assessment of association with end-stage renal disease (ESRD) in the total cohort and assessment of association with the intermediate phenotypes in distinct subgroups where the detailed phenotypes were available. The selection flowchart of the study is shown in Fig. 1 eters, and clinical and laboratory data were retrieved from medical records.
1) The total cohort consisted of 1,184 kidney donors and 1,141 first-graft recipients (1,066 matched donor-recipient pairs), assessed post hoc from all renal transplantations in our center between 1993 and 2008, excluding cases of retransplantation, combined kidney/ pancreas or kidney/liver transplantation, technical problems, absence of DNA, and loss of follow-up. After transplantation the recipients were followed up during median [IQR] 5.5 [3.0 -8.7] yr for graft failure (GF) defined as return to dialysis or retransplantation, censored for death with a functioning graft. Allele frequency in recipients vs. donors was analyzed in a case-control approach to test for the association of SLC22A2 with ESRD. Follow-up data in the recipients were used for analysis of association with GF.
2) Data on 125 I-iothalamate clearance at 1 yr after transplantation, serum creatinine, and creatinine clearance from 24 h urine, collected the day before 125 I-iothalamate clearance measurements, were available for 738 recipients. These data were used to assess the association of SLC22A2 with the bias of eGFR.
3) Simultaneously measured 2 h clearances of creatinine and 125 I-iothalamate were available in 348 recipients, studied at median [IQR] 3.5 [1.7-6.9] yr after transplantation. These data were used to calculate FEcreat and analyze for its association with SLC22A2. The overlap between the subgroups of patients with true GFR and FE creat measurements (n ϭ 738 and n ϭ 348, respectively) was 264 cases.
The Institutional Review Board of the University Medical Center Groningen approved the study protocol. Written informed consent was given by all recipients and living donors. For deceased donors, with research carried out after the organ removal and implantation, no consent was required by Dutch law. The study was conducted according to the principles of the Declaration of Helsinki. All the data were anonymized prior to analyses.
Treatment protocols and renal function measurement. The treatment regimen in our transplant population has been described in more detail elsewhere (13). In brief, standard immunosuppression consisted of cyclosporine microemulsion (10 mg/kg trough-levels idem, Neoral, Novartis; Pharma, Arnhem, the Netherlands) and prednisolone from March 1993 until May 1996; mycophenolate mofetil (2 g/day Cellcept; Roche Nederland, Woerden, the Netherlands) was added from May 1997 to date.
The routine follow-up includes measurement of true GFR at regular intervals by 125 I-iothalamate clearance, as described in detail by Visser et al. (55) . Creatinine clearance was also measured as a routine, from 24 h urine collected on the day preceding the GFR assessment. As of 2006 simultaneous measurement of creatinine clearance was included in the protocol, as described in detail by Sinkeler et al. (46) . In brief, serum and 2 h urine creatinine measurements were obtained during the measurement of 125 I-iothalamate GFR, and FEcreat was calculated as (U/P) creat/(U/P)iot from the same samples as the 125 Iiothalamate clearance, thus avoiding discrepancies due to collection errors and diurnal changes in renal function. Creatinine was measured with the Roche enzymatic creatinine assay, which is isotope dilution mass spectrometry-traceable. The assay was calibrated to the reference standard (Cleveland Clinic Laboratory measurements), as proposed by Coresh et al. (11) and described in more detail by Tent et al. (50) .
DNA isolation and genotyping. DNA was extracted from peripheral whole blood (in recipients and living donors) or lymph nodes/spleen lymphocytes (in deceased donors) using a commercial kit following the manufacturer's instructions, transferred into 2 ml Eppendorf tubes, and stored at Ϫ20°C. Absorbance at 260 nm was measured with NanoDrop spectrophotometer (ND-1000, NanoDrop Technologies), and DNA concentration was calculated by the NanoDrop nucleic acid application module. As a measure of DNA purity, 260/280 and 260/230 absorbance ratios were assessed. Where samples failed to meet the minimum DNA concentration and purity recommended for Illumina genotyping, repeated isolation attempts were made. Genotyping of rs316019 was not possible for technical reasons as the polymorphism was not supported by the used assay. Instead we genotyped rs316009, an intronic SLC22A2 SNP that is in perfect LD (r 2 ϭ 1.0) with rs316019. Genotyping of the selected SNPs, rs3127573 and rs316009, was performed using the Illumina VeraCode GoldenGate assay kit (Illumina, San Diego, CA), according to the manufacturer's instructions. Genotype clustering and calling were performed with BeadStudio Software (Illumina).
Statistical analysis. Analyses were performed with PASW Statistics 18.0 (SPSS, Chicago, IL) and PLINK v1.07 [S. Purcell, http:// pngu.mgh.harvard.edu/purcell/plink/ (37)].
Genotype-phenotype associations were tested under an additive genetic model, and results (regression coefficients and P values) are reported per copy of the minor allele.
Association between the SLC22A2 SNPs and FE creat was studied with linear regression. Relevant covariates [age, sex, body mass index (BMI), drug use] were included in the multivariate model. Drugs use was coded as yes/no cotrimoxazole and cyclosporin A/tacrolimus/no calcineurin inhibitor.
MDRD (25, 26) , CKD-EPI (27) , and Cockroft-Gault (10) equations were used to calculate eGFR. We analyzed predictive performance of the equations for GFR estimation by assessing their precision (the scatter of the observations and expressed as R 2 ), 30 and 10% accuracy (the percentage of subjects within, respectively, 30 and 10% of true GFR, i.e., 125 I-iothalamate clearance), and bias [the mean prediction error calculated as Α(predicted value Ϫ true value)/n] (2).
Statistical significance of differences in renal function, its estimates, and bias of GFR estimation between the SLC22A2 SNPs genotypes was tested with Kruskal-Wallis test (similar to the general genotypic 2df-test).
We tested association with ESRD in a case-control design by comparing 1,141 ESRD patients admitted for renal transplantation and 1,184 kidney donors. The PLINK DFAM algorithm was used to account for case-control relatedness within living-donor transplantation cases.
The effect of the SNPs on graft survival was studied in 1,066 renal transplant recipients. A Cox regression analysis was performed including known predictors of GF (donor and recipient age and sex, donor type, ischemia times, delayed graft function and acute rejection episodes history, immunosuppressive drugs) as covariates in a multivariate model. Kaplan-Meier survival curves were built for analysis and visualization of graft survival in genotypic groups, and the log rank test was used to test for significance of differences between the curves.
RESULTS
Main patient characteristics are presented in Table 1 for the  total cohort and Table 2 for the subgroups. In the total cohort, the minor allele frequencies were 11.6% for rs316009 and 13.2% for rs3127573. There was no deviation from HardyWeinberg equilibrium in controls Ϫ donors (P ϭ 0.47 and P ϭ 1.00 for rs316009 and rs3127573, respectively). There was no LD between the two SNPs (r 2 ϭ 0.002 in our cohort, r 2 ϭ 0.008 in HapMap release 22 CEU population).
Association of the SLC22A2 variants with FE creat , renal function estimates, and performance of eGFR. In 348 recipients FE creat was assessed from simultaneous clearances of creatinine and 125 I-iothalamate. It ranged from 0.71 (min) to 1.39 (max) (Fig. 2) , with a mean of 1.05, indicating a 5% mean contribution of tubular secretion to creatinine clearance. Determinants of FE creat are given in Table 3 displaying univariate effects of donor and recipient characteristics and the multivariate linear regression model. The donor kidney rs316009 (the proxy SNP for the functional rs316019) was associated with lower FE creat in an allele dose-dependent manner (beta Ϫ0.053 per copy of the minor allele, P ϭ 0.024) in the model, which included donor age and sex, recipient age, sex, BMI, use of cotrimoxazole, and type of calcineurin inhibitor (r 2 of the model was 0.31). Per donor rs316009 homozygous by the ancestral allele (n ϭ 280), heterozygous (n ϭ 61), and homozygous by the minor allele (n ϭ 7) genotypes, FE creat (mean Ϯ SD) was 1.06 Ϯ 0.19, 1.02 Ϯ 0.18 and 0.99 Ϯ 0.18, respectively.
Association analyses of renal function, its estimates, and performance of eGFR were conducted in 738 recipients at 1 yr posttransplantation. Precision (R 2 ) of the GFR estimation methods was 0.59, 0.60, and 0.48 for MDRD, CKD-EPI, and Cockcroft-Gault formulas, respectively; 10 and 30% accuracy were 23.8 and 74.3%, 29.8 and 81.8%, 29.5 and 76.0% for MDRD, CKD-EPI, and Cockcroft-Gault equations, respectively.
Data on renal function and renal function estimates are given in Table 4 by a breakup by donor kidney genotype. There was no difference in serum creatinine or creatinine clearance between the genotypes. Measured GFR was not different between the genotypes either. However, MDRD and CKD-EPI eGFR was slightly but significantly higher with each copy of the rs316009 minor allele in the kidney genotype (P ϭ 0.016 and P ϭ 0.022 for MDRD and CKD-EPI, respectively). This was paralleled by a decrease in GFR estimation bias of MDRD and CKD-EPI equations across the rs316009 genotypes, with eGFR closely approximating actual GFR in the minor allele homozygotes. Cockcroft-Gault equation performance was not affected by the genotypes. The rs3127573 was not significantly associated with renal function estimates.
Association of the SLC22A2 variants with phenotypes of renal function loss: ESRD and GF. The genotypes of the studied SLC22A2 variants were unequally distributed between the ESRD patients and kidney donors. There were more carriers of both SNPs minor alleles among ESRD patients than among donors. Correspondingly, the MAFs of rs3127573 and rs316009 were significantly higher in ESRD patients (14.9 and 12.9%, respectively) compared with kidney donors (11.4 and 10.6%, respectively), implying an increased risk of ESRD in association with the minor allele. (Table 6) . Log rank test showed P ϭ 0.530 and P ϭ 0.078 for significance of differences between the graft survival curves by donor rs316009 and rs3127573 genotypes, respectively. None of the SNPs was associated with overall or cardiovascular mortality in recipients (not shown). 
DISCUSSION
This study in renal transplant recipients reports a significant association between donor SLC22A2 SNP rs316009 and FE creat , with lower FE creat in the presence of one or two minor alleles. An association was found between rs316009 and eGFR (MDRD and CKD-EPI), but not with measured GFR. In line with this, bias of the eGFR equations was significantly associated with rs316009. In line with prior data in healthy subjects, age, sex, and BMI were environmental determinants of FE creat . Remarkably, both SLC22A2 SNPs were associated with the increased risk for ESRD in native kidneys. Thus, genetic variation in SLC22A2 can modulate net tubular creatinine handling, hence affecting the bias of the main renal function equations that are calibrated on measured GFR. The association with ESRD is in line with a role for tubular functions in progressive renal function loss, and deserves further substantiation.
By the required sample size, GWAS for renal function usually rely on simple renal function estimates, mostly serum creatinine and eGFR creat (7), sometimes complemented by renal function estimates with cystatin C (23, 24) , to account for the shortcomings of serum creatinine and/or eGFR for renal function assessment. Dissociation in outcomes for association with creatinine and cystatin C (34) is useful to separate genetic loci that are related to true GFR from loci that affect creatinine level by creatinine generation or tubular secretion. Thus, the SLC22A2 locus emerges as a locus likely to influence creatinine secretion rather than true GFR (24), as supported by the current study.
Tubular secretion of creatinine has wide interindividual variability (35, 45) . We show that genetic variation in the SLC22A2 locus, i.e., the SLC22A2 SNP rs316009, in the donor kidney is an independent determinant of FE creat . The lower FE creat per copy of the rs316009 minor allele is consistent with prior in vitro studies, showing that the correlated polymorphism, rs316019, which we assumed to be the true causal variant tagged by rs316009, resulted in decreased transport of OCT2 substrates (8, 15, 48, 57, 61) .
In line with data in healthy subjects, FE creat was associated with age, sex, and BMI, supporting the robustness of this phenotype and its determinants (46) . Our current data, for the first time, show that genetic factors are also involved in FE creat , demonstrating its nature as a complex, environmentally as well as genetically determined, phenotype. Age, sex, and BMI are all related to muscle mass and hence creatinine supply, a possible common denominator in the association with tubular creatinine secretion. Of note, these factors can influence creatinine transporter expression. In rodents, pronounced sexual dimorphism in renal SLC22A2 expression was reported, with higher mRNA levels (47) and greater transport of OCT2 substrates in renal slices from male rats (53) . In line with this, testosterone upregulates and estradiol moderately downregulates rOCT2 renal expression in rats (54) .
Drug use, in particular trimethoprim, might affect FE creat (14, 21, 22, 33) . In the 19 patients on cotrimoxazole in our study, however, we found no effect on FE creat , possibly due to lack of statistical power or the low dose of cotrimoxazole. The type of calcineurin inhibitor (cyclosporin A or tacrolimus), however, affected FE creat , although an older report found no effect of cyclosporine A on tubular transport of creatinine (19) .
In our patients average FE creat was 1.05, ranging from 0.71 to 1.39. Thus, average FE creat was slightly lower, and interindividual variability larger than in our prior study in healthy subjects (46) . Together, this resulted in a relatively high proportion of subjects with FE creat Ͻ1, i.e., subjects with net tubular creatinine reabsorption. Of note, the methodology was similar in two our studies, so the differences in FE creat between them must be due to patient characteristics. The large betweenpatient variability in FE creat is in line with a prior small study in renal transplant recipients by Schück et al. (45) , who also noted FE creat Ͻ1, calculated as the ratio of creatinine to polyfructosan clearance, in some patients. Creatinine reabsorption, albeit infrequent, has been described previously (30, 31, 35, 45) . It is considered physiological in newborns and the elderly and is attributed to tubular characteristics allowing for "back-leak" of creatinine, namely an immature tubular structure with increased permeability in newborns and tubular atrophy in the elderly, respectively (30, 31) . Moreover, it has been reported in pathological conditions, such as decompensated heart failure or uncontrolled diabetes (35) . All prior studies, however, were small, precluding a reliable estimation of the frequency of FE creat Ͻ1. Of note, absolute values of FE creat depend on the assessment of GFR, and to compare studies from different centers, the properties of the GFR tracer must be taken into account. We used iothalamate; its clearance is on the average 8% higher than inulin clearance (3, 4, 36), so the calculated FE creat will be correspondingly lower. Simulating the use of inulin, i.e., calculating FE creat from 8% lower GFR, the proportion of subjects with FE creat Ͻ1 would have been 30.8% (data not shown).
The mechanisms underlying the differences in FE creat between the current transplant recipients and the previously studied healthy subjects would be of interest. As our study was not designed to address that issue, however, we can only speculate. Between-patient variability in tubulo-interstitial damage, in drug use, or in endogenous circulating factors affecting OCT expression or function, could be involved (14, 21, 22, 33, 41) . Further studies would be needed to explore this issue. In line with the effect on FE creat , bias of the MDRD and CKD-EPI equation was significantly associated with the rs316009 minor allele, with a net difference in bias of ϳ9 ml/min between homozygotes for the ancestral and the minor alleles for both equations. No such effect on bias was found for the Cockroft-Gault equation, which is in line with its calibration on creatinine clearance. Thus, genetic variability in tubular creatinine handling can induce a systematic error in assessment of eGFR by creatinine-based equations that can lead to spurious associations with eGFR.
Remarkably, and unexpectedly, the SLC22A2 SNPs were associated with prevalent ESRD with an increased odds ratio for ESRD for the minor alleles of both SNPs. This is in line with the increasing recognition of the role of tubulo-interstitium in the pathophysiology of renal disease and, accordingly, the notion that an integrative measure of both glomerular and tubular function may bear more prognostic relevance than a specific measure for GFR only (42) . Considering the substrate polyspecificity of OCT2 (59), reduced tubular secretion of various candidate substances might potentially be involved, Cox regression analyses were run under the additive genetic model, the coefficients are presented per copy of the minor allele. HR, hazard ratio; CI, confidence interval. *Adjusted for donor and recipient age and sex, donor type (living vs. deceased), cold ischemia duration, history of delayed graft function and acute rejection episodes, immunosuppression drugs.
including catecholamines, dopamine, prostaglandins, advanced glycation end products, and, possibly, uremic toxins, that could affect the kidney either directly or by effects on blood pressure and volume status and hence promote progressive renal damage (16, 20, 28, 32, 56, 60) . Finally, the association with ESRD as indicator for the susceptibility to renal damage is corroborated by recent GWAS data reporting a suggestive association between rs316019 and diabetic nephropathy (43) .
We did not observe an association between the donor kidney SLC22A2 SNPs and GF. Although the SNPs effect was direction-consistent with the case-control analysis of ESRD in native kidney, the results were not statistically significant. It might indicate true absence of an association or lack of power to detect a genetic effect on GF and warrants further investigation in larger transplant populations.
The strength of our study lies in its specific design and the detailed renal phenotype. However, limitations should be mentioned. Our work was a single-center study in a predominantly Caucasian population, which limits generalizability, and we acknowledge an inherent selection bias within ESRD cases toward patients eligible for transplantation. The results on the detailed renal phenotype were obtained in renal transplant recipients only and hence cannot be generalized to native kidneys. Finally, our in vivo clinical approach only allows solid conclusions on net creatinine handling, and assumptions on OCT2 rely on inference.
Significance/Implications
Our study represents a hypothesis-driven in vivo follow-up of prior GWAS and in vitro studies. It introduces FE creat as a novel renal phenotype in genetic studies. FE creat , reflecting net tubular creatinine secretion, is a complex phenotype with age, BMI, and sex as environmental determinants. We now show that SLC22A2 genotype is associated with FE creat and accordingly, with bias of eGFR. Thus, genetic variability of tubular creatinine handling should be taken into account in GWAS analyses on creatinine-based renal function phenotypes, and in this respect profiling the SLC22A2 variants can improve eGFR performance. Finally, the association of SLC22A2 SNPs with ESRD is consistent with a role of tubular integrity in the protection against progressive renal damage, but requires further substantiation.
